The proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor evolocumab reduces the risk of major adverse cardiovascular events (MACE) among patients with a previous myocardial infarction, ...

Myocardial infarction, commonly known as a heart attack, is one of the most serious heart problems people can face. It happens when blood flow to a part of the heart muscle is suddenly blocked.

Most trials that have shown a benefit of beta-blocker treatment after myocardial infarction included patients with large myocardial infarctions and were conducted in an era before modern ...

A pioneering study by researchers from Finland and the UK has demonstrated for the first time that myocardial infarction may be an infectious disease. This discovery challenges the conventional ...

Type 1 diabetes confers a cardiovascular burden that is often obscured by the young age of affected individuals and by the ...